SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
Research students Sheera Rosenbaum, left, and Kaiah Fields, right, work in the lab at the CU Anschutz Cancer Center in Aurora, Colorado on March 18, 2025.
(Photo: Helen H. Richardson/MediaNews Group/The Denver Post via Getty Images)
'Devastating' Trump Cuts to FDA, NIH Will Result in Fewer Medications, New Analysis Warns
"The United States' effort to bring cutting-edge treatments to patients," said a group of lawmakers, "will come to a grinding halt because of the Trump administration's devastating cuts to NIH and FDA funding."
Jul 18, 2025
One former federal health official said Friday that medications with the potential to "substantially change healthcare and improve the lives of patients" are likely to be among the dozens that won't be developed if Republicans pass a proposal by the Trump administration to slash crucial health research funding.
Jeremy Berg, a former director of the National Institute of General Medical Sciences at the National Institutes of Health, was referring to an analysis by the Congressional Budget Office (CBO) of President Donald Trump's proposal to cut funding to the NIH by 40%—budget cuts that experts have warned would kneecap the country's ability to research emerging health threats and treatments, while terminating the United States' position as a world leader in medical innovation.
"The lost drugs" resulting from the budget cuts, Berg told The New York Times, "are more likely to be the novel 'first in class' drugs."
The CBO found that even a 10% reduction in the NIH budget would stop an estimated 30 new medications from coming to market over the next three decades.
A reduction in the agency's external preclinical research "would ultimately decrease the number of new drugs coming to market by roughly 4.5%, or about two drugs per year," the CBO said, with the impact of the budget cuts growing over three decades.
The CBO also analyzed proposals that would affect the Food and Drug Administration (FDA), including one that would cut staff and result in increased review times for new medications by nine months. By the second decade of the policy being in effect, said the CBO, 10 fewer drugs would be approved each decade—a 2% reduction—with 23 new medications ultimately being prevented from coming to market.
Already, the FDA's workforce has been reduced by about 15%, with 3,500 people losing their jobs or resigning.
The Times reported that the FDA has approved 25 new drugs so far in 2025; it has authorized an average of 60 new medications per year in the past.
"This unprecedented assault on our healthcare institutions by the Trump administration will cut off access to medicines that patients are waiting for, cede our global leadership in medical innovation to China, and cause wide-ranging harms to our nation's economy."
A group of Democratic lawmakers who serve as ranking members of key committees emphasized that the CBO's analysis likely vastly underestimates the impact Trump's proposed cuts would have on the NIH, as it investigated the potential impact of just a 10% budget cut rather than the full 40% cut the president has proposed.
"The proposed cuts are so enormous that CBO's own model is unable to produce an estimate," said U.S. Reps. Brendan Boyle (D-Pa.), ranking member of the House Budget Committee, and Frank Pallone (D-N.J.), along with Sens. Bernie Sanders (I-Vt.) and Jeff Merkley (D-Ore.).
"The United States leads the world in medical innovation because of our continued investments in research and development at the NIH," said the lawmakers. "Every $1 invested in NIH research returns $2.50 to the U.S. economy. This unprecedented assault on our healthcare institutions by the Trump administration will cut off access to medicines that patients are waiting for, cede our global leadership in medical innovation to China, and cause wide-ranging harms to our nation's economy."
"The United States' effort to bring cutting-edge treatments to patients with cancers, rare diseases, cardiovascular diseases, and neurodegenerative diseases," they added, "will come to a grinding halt because of the Trump administration's devastating cuts to NIH and FDA funding."
An Urgent Message From Our Co-Founder
Dear Common Dreams reader, It’s been nearly 30 years since I co-founded Common Dreams with my late wife, Lina Newhouser. We had the radical notion that journalism should serve the public good, not corporate profits. It was clear to us from the outset what it would take to build such a project. No paid advertisements. No corporate sponsors. No millionaire publisher telling us what to think or do. Many people said we wouldn't last a year, but we proved those doubters wrong. Together with a tremendous team of journalists and dedicated staff, we built an independent media outlet free from the constraints of profits and corporate control. Our mission has always been simple: To inform. To inspire. To ignite change for the common good. Building Common Dreams was not easy. Our survival was never guaranteed. When you take on the most powerful forces—Wall Street greed, fossil fuel industry destruction, Big Tech lobbyists, and uber-rich oligarchs who have spent billions upon billions rigging the economy and democracy in their favor—the only bulwark you have is supporters who believe in your work. But here’s the urgent message from me today. It's never been this bad out there. And it's never been this hard to keep us going. At the very moment Common Dreams is most needed, the threats we face are intensifying. We need your support now more than ever. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. When everyone does the little they can afford, we are strong. But if that support retreats or dries up, so do we. Will you donate now to make sure Common Dreams not only survives but thrives? —Craig Brown, Co-founder |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
food and drug administrationhealthcarenational institutes of healthpublic healthwar on sciencetrump administration
One former federal health official said Friday that medications with the potential to "substantially change healthcare and improve the lives of patients" are likely to be among the dozens that won't be developed if Republicans pass a proposal by the Trump administration to slash crucial health research funding.
Jeremy Berg, a former director of the National Institute of General Medical Sciences at the National Institutes of Health, was referring to an analysis by the Congressional Budget Office (CBO) of President Donald Trump's proposal to cut funding to the NIH by 40%—budget cuts that experts have warned would kneecap the country's ability to research emerging health threats and treatments, while terminating the United States' position as a world leader in medical innovation.
"The lost drugs" resulting from the budget cuts, Berg told The New York Times, "are more likely to be the novel 'first in class' drugs."
The CBO found that even a 10% reduction in the NIH budget would stop an estimated 30 new medications from coming to market over the next three decades.
A reduction in the agency's external preclinical research "would ultimately decrease the number of new drugs coming to market by roughly 4.5%, or about two drugs per year," the CBO said, with the impact of the budget cuts growing over three decades.
The CBO also analyzed proposals that would affect the Food and Drug Administration (FDA), including one that would cut staff and result in increased review times for new medications by nine months. By the second decade of the policy being in effect, said the CBO, 10 fewer drugs would be approved each decade—a 2% reduction—with 23 new medications ultimately being prevented from coming to market.
Already, the FDA's workforce has been reduced by about 15%, with 3,500 people losing their jobs or resigning.
The Times reported that the FDA has approved 25 new drugs so far in 2025; it has authorized an average of 60 new medications per year in the past.
"This unprecedented assault on our healthcare institutions by the Trump administration will cut off access to medicines that patients are waiting for, cede our global leadership in medical innovation to China, and cause wide-ranging harms to our nation's economy."
A group of Democratic lawmakers who serve as ranking members of key committees emphasized that the CBO's analysis likely vastly underestimates the impact Trump's proposed cuts would have on the NIH, as it investigated the potential impact of just a 10% budget cut rather than the full 40% cut the president has proposed.
"The proposed cuts are so enormous that CBO's own model is unable to produce an estimate," said U.S. Reps. Brendan Boyle (D-Pa.), ranking member of the House Budget Committee, and Frank Pallone (D-N.J.), along with Sens. Bernie Sanders (I-Vt.) and Jeff Merkley (D-Ore.).
"The United States leads the world in medical innovation because of our continued investments in research and development at the NIH," said the lawmakers. "Every $1 invested in NIH research returns $2.50 to the U.S. economy. This unprecedented assault on our healthcare institutions by the Trump administration will cut off access to medicines that patients are waiting for, cede our global leadership in medical innovation to China, and cause wide-ranging harms to our nation's economy."
"The United States' effort to bring cutting-edge treatments to patients with cancers, rare diseases, cardiovascular diseases, and neurodegenerative diseases," they added, "will come to a grinding halt because of the Trump administration's devastating cuts to NIH and FDA funding."
One former federal health official said Friday that medications with the potential to "substantially change healthcare and improve the lives of patients" are likely to be among the dozens that won't be developed if Republicans pass a proposal by the Trump administration to slash crucial health research funding.
Jeremy Berg, a former director of the National Institute of General Medical Sciences at the National Institutes of Health, was referring to an analysis by the Congressional Budget Office (CBO) of President Donald Trump's proposal to cut funding to the NIH by 40%—budget cuts that experts have warned would kneecap the country's ability to research emerging health threats and treatments, while terminating the United States' position as a world leader in medical innovation.
"The lost drugs" resulting from the budget cuts, Berg told The New York Times, "are more likely to be the novel 'first in class' drugs."
The CBO found that even a 10% reduction in the NIH budget would stop an estimated 30 new medications from coming to market over the next three decades.
A reduction in the agency's external preclinical research "would ultimately decrease the number of new drugs coming to market by roughly 4.5%, or about two drugs per year," the CBO said, with the impact of the budget cuts growing over three decades.
The CBO also analyzed proposals that would affect the Food and Drug Administration (FDA), including one that would cut staff and result in increased review times for new medications by nine months. By the second decade of the policy being in effect, said the CBO, 10 fewer drugs would be approved each decade—a 2% reduction—with 23 new medications ultimately being prevented from coming to market.
Already, the FDA's workforce has been reduced by about 15%, with 3,500 people losing their jobs or resigning.
The Times reported that the FDA has approved 25 new drugs so far in 2025; it has authorized an average of 60 new medications per year in the past.
"This unprecedented assault on our healthcare institutions by the Trump administration will cut off access to medicines that patients are waiting for, cede our global leadership in medical innovation to China, and cause wide-ranging harms to our nation's economy."
A group of Democratic lawmakers who serve as ranking members of key committees emphasized that the CBO's analysis likely vastly underestimates the impact Trump's proposed cuts would have on the NIH, as it investigated the potential impact of just a 10% budget cut rather than the full 40% cut the president has proposed.
"The proposed cuts are so enormous that CBO's own model is unable to produce an estimate," said U.S. Reps. Brendan Boyle (D-Pa.), ranking member of the House Budget Committee, and Frank Pallone (D-N.J.), along with Sens. Bernie Sanders (I-Vt.) and Jeff Merkley (D-Ore.).
"The United States leads the world in medical innovation because of our continued investments in research and development at the NIH," said the lawmakers. "Every $1 invested in NIH research returns $2.50 to the U.S. economy. This unprecedented assault on our healthcare institutions by the Trump administration will cut off access to medicines that patients are waiting for, cede our global leadership in medical innovation to China, and cause wide-ranging harms to our nation's economy."
"The United States' effort to bring cutting-edge treatments to patients with cancers, rare diseases, cardiovascular diseases, and neurodegenerative diseases," they added, "will come to a grinding halt because of the Trump administration's devastating cuts to NIH and FDA funding."
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.